Evofem Biosciences Addresses Impact Of GLP-1 Medications On Oral Contraceptive Absorption And Introduces Phexxi As A Non-Oral Solution

As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB:EVFM) is raising awareness of the potential impact these medications may have on the effectiveness of oral contraceptives. With an increasing number of women turning to GLP-1 medications for weight management and glycemic control, the need for reliable non-oral contraceptive options has never been more acute.